SABS
SAB Biotherapeutics, Inc.- Healthcare
- Biotechnology
- $258M market cap
Forecast run · Oct 29, 2026Upside rank 1690 of 3,186
Model Signal
ForecastQ Daily Probabilities
24.3%
73.6%
17.5%
Analyst Consensus
Recommendation2.13/5 Buy
Last price$2.84
Price target$11.33
Implied move+298.9%
Analysts8
ForecastQ Portfolios
Company Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.